Skip to main content

Advertisement

Table 1 Comparison of baseline characteristics between patients with and without foot or ankle RA involvement

From: Impact of midfoot and Hindfoot involvement on functional disability in Korean patients with rheumatoid arthritis

Variables No RA involvement in the foot or ankle, n = 46 RA involvement in the foot or ankle, n = 74 P value
Age, median (IQR), years 45.5 (36.8–54.0) 50.5 (38.75–58.0) 0.09
Disease duration, median (IQR), months 47.5 (7.50–80.0) 63.0 (12.3–103.3) 0.09
BMI, median (IQR), kg/m2 21.7 (20.5–24.0) 22.9 (20.2–25.0) 0.35
Patient global assessment, VAS (0–10), median (IQR) 15.0 (10.0–30.0) 30.0 (10.0–40.0) <0.05
CRP, median (IQR), mg/dl 0.40 (0.34–0.95) 0.40 (0.15–1.13) 0.97
ESR, median (IQR), mm/h 18.5 (10.0–40.0) 27.0 (11.8–43.0) 0.35
DAS28-ESR, median (IQR) 3.07 (2.50–4.10) 4.08 (3.05–5.07) <0.05
Female, n (%) 45 (97.8) 68 (91.9) 0.25
RF positive, n (%) 39 (84.8) 65 (87.8) 0.63
ACPA positive, n (%) 42 (91.3) 65 (89.0) 0.86
Medications, n (%)
 Glucocorticoid 35 (76.1) 54 (73.0) 0.71
 NSAID 38 (82.6) 67 (90.5) 0.20
 Methotrexate 44 (95.7) 67 (90.5) 0.48
 Conventional DMARDsa 45 (97.8) 72 (97.3) 1.00
 Biologic DMARDsb 7 (15.2) 33 (44.6) <0.05
EQ-5D, median (IQR) 0.81 (0.75–0.86) 0.76 (0.69–0.84) <0.05
HAQ-DI (0–3), median (IQR) 0.38 (0–0.5) 0.63 (0.13–1.16) <0.05
RA involvement, n (%)
 Forefoot 0 32 (43.2) NA
 Midfoot 0 24 (32.4) NA
 Hindfoot 0 46 (62.2) NA
 Ankle 0 4 (5.4) NA
Foot deformity, n (%)
 Hallux valgus, 8 (17.4) 18 (24.3) 0.37
 Metatarsus primus varus 16 (34.8) 22 (29.7) 0.56
 Splayfoot 0 2 (2.7) 0.52
 Pes planus 43 (93.5) 71 (95.9) 0.67
  1. ACPA anti-cyclic citrullinated protein antibody, BMI body mass index, CRP C-reactive protein, DAS28 disease activity score 28, DMARDs disease-modifying antirheumatic drugs, ESR erythrocyte sedimentation rate, EQ-5D EuroQol five-dimension questionnaire, HAQ-DI Health Assessment Questionnaire-Disability Index, IQR interquartile range, NA not applicable, NSAID non-steroidal anti-inflammatory drug, RF rheumatoid factor, SD standard deviation, VAS visual analogue scale
  2. aConventional DMARDs include methotrexate, hydroxychloroquine, sulfasalazine and leflunomide
  3. bBiologic DMARDs include adalimumab, etanercept, golimumab, abatacept and rituximab